Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Trial update on watchful waiting versus radical prostatectomy

In 2005, the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported that radical prostatectomy improved prostate cancer survival compared with watchful waiting after a median of 8.2 years of follow-up.

22 Mar 2009

New therapeutic approaches to castrate resistant prostate cancer

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24 th Annual Congress of the European Association of Urology in Stockholm, Sweden.

22 Mar 2009

PSA screening delivers a 20% reduction in mortality from prostate cancer

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online in at NEJM, Online First.

20 Mar 2009

Improvements in prostate cancer recognition, management and treatment are needed

The prostate cancer charter for change from 13 influential European and US prostate cancer patient groups, calls for the disease to be treated with the same level of priority as breast cancer is in women.

20 Mar 2009

Prostate cancer expert say keep screening in face of contradicting data

New data evaluating the impact of screening on mortality provides mixed messages on the value of prostate cancer screening.

20 Mar 2009

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

A multi-center study of prostate cancer patients appearing in today's Journal of Urology recommends that for some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

16 Mar 2009

Identification of triggering mechanism by which breast and prostate cancer cells begin

Dr. Ercole Cavalieri and Dr. Eleanor Rogen of the University of Nebraska Medical Center, Eppley Institute for Research in Cancer, located in Omaha, Nebraska, have identified the triggering mechanism by which breast and prostate cancer cells begin. Preventium is a recently developed dietary supplement that promises to reduce people's risk for breast and prostate cancer.

16 Mar 2009

Promising results for 5-day stereotactic body radiation therapy in early stage prostate cancer

Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments, according to a March 15 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology (ASTRO).

16 Mar 2009

New investigational therapy for the treatment of bladder cancer

A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer.

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

Discovery of cellular pathway that prevents cancer response to diet restriction

Whitehead Institute researchers have pinpointed a cellular pathway that determines whether cancerous tumors respond to dietary restriction during their development.

11 Mar 2009

Cell pathway on overdrive prevents cancer response to dietary restriction

Whitehead Institute researchers have pinpointed a cellular pathway that determines whether cancerous tumors respond to dietary restriction during their development.

11 Mar 2009

Study methods influence estimates of lead time and overdiagnosis in prostate cancer

In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient's lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Small molecules block cancer gene

Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing gene to those of the small molecules, said a Baylor College of Medicine researcher in a report that appears in the current online issue of the journal PLoS One (Public Library of Science ONE).

11 Mar 2009

Folic acid appears to double risk for prostate cancer

A study led by researchers at the University of Southern California (USC) found that men who took a daily folic acid supplement of 1 mg daily had more than twice the risk of prostate cancer compared with men who took a placebo.

11 Mar 2009

Color of wine makes no difference when it comes to breast-cancer

The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk.

10 Mar 2009

Male lumpectomy - first line treatment for prostate cancer

The so-called "male lumpectomy" - a minimally invasive interventional radiology treatment for prostate cancer - is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009